Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Bristol-Myers Squibb (BMS)

Status and phase: Withdrawn; Phase 1

Conditions: Leukemia, Myeloid, Chronic

Treatments: Biological: Ipilimumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00732186

CA184-033

Details and patient eligibility

About

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ph+ CML on dasatinib therapy
• Loss of cytogenetic or molecular response while on dasatinib therapy
• On stable dose of dasatinib for a minimum of 12 weeks and with < 14 day interruption of treatment

Exclusion criteria

• Blast crisis CML
• Autoimmune disease
• Uncontrolled or significant cardiovascular disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Group 1 and Group 2

Experimental group

Treatment:

Biological: Ipilimumab